Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
MustGrow Biologics ( (TSE:MGRO) ) has issued an update.
MustGrow Biologics Corp. reported record Q2-2025 results with $2.8 million in revenue and a 20.9% gross profit margin, driven by strong sales of its TerraSante biofertility product in the U.S. The company sold out its TerraSante inventory, tripling its sales compared to 2024, and is working to meet increasing demand. Despite a net loss of $1.1 million, MustGrow is optimistic about its growth prospects, focusing on revenue growth through its NexusBioAg division in Canada and TerraSante sales in the U.S. The company aims to finish the year with strong Q4 results.
Spark’s Take on TSE:MGRO Stock
According to Spark, TipRanks’ AI Analyst, TSE:MGRO is a Neutral.
MustGrow Biologics’ overall stock score of 57 reflects significant revenue growth and strategic market expansions, countered by ongoing financial challenges and valuation concerns. The company’s strong gross margins and low leverage are positives, but the persistent net losses and negative cash flow remain crucial risks.
To see Spark’s full report on TSE:MGRO stock, click here.
More about MustGrow Biologics
MustGrow Biologics Corp. is a fully-integrated provider of innovative biological and regenerative agriculture solutions aimed at supporting sustainable farming. The company offers eco-friendly alternatives to synthetic chemicals and fertilizers through its proprietary and third-party product lines. In North America, MustGrow provides a range of crop nutrition solutions, while outside North America, it collaborates with agriculture companies like Bayer AG to commercialize its products. MustGrow is committed to expanding its intellectual property portfolio and enhancing shareholder value.
Average Trading Volume: 13,158
Technical Sentiment Signal: Sell
Current Market Cap: C$39.25M
Learn more about MGRO stock on TipRanks’ Stock Analysis page.